Pfizer (NYSE:PFE) Trading Down 1.3% – Time to Sell?

25 Dec 2025, 13:10 by Amy Steele · The Cerbat Gem

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) dropped 1.3% on Tuesday . The company traded as low as $24.83 and last traded at $24.8850. Approximately 43,181,467 shares were traded during trading, a decline of 16% from the average daily volume of 51,487,402 shares. The stock had previously closed at $25.21.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research analyst reports. Bank of America reduced their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. UBS Group reissued a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Finally, Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.06.

Get Our Latest Research Report on Pfizer

Pfizer Stock Performance

The stock has a 50 day moving average of $25.13 and a 200 day moving average of $24.88. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The firm has a market cap of $142.40 billion, a price-to-earnings ratio of 14.56 and a beta of 0.46.

Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s dividend payout ratio is 100.00%.

Institutional Trading of Pfizer

A number of hedge funds have recently added to or reduced their stakes in PFE. Brighton Jones LLC increased its holdings in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC grew its position in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. PKS Advisory Services LLC increased its stake in shares of Pfizer by 7.0% in the first quarter. PKS Advisory Services LLC now owns 13,044 shares of the biopharmaceutical company’s stock valued at $327,000 after buying an additional 849 shares during the period. FORA Capital LLC bought a new position in shares of Pfizer during the first quarter worth about $439,000. Finally, Epoch Investment Partners Inc. lifted its stake in shares of Pfizer by 2.9% in the first quarter. Epoch Investment Partners Inc. now owns 2,128,420 shares of the biopharmaceutical company’s stock worth $53,934,000 after acquiring an additional 59,811 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

(Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.